封面
市場調查報告書
商品編碼
1732853

口服抗糖尿病藥物市場-全球產業規模、佔有率、趨勢、機會和預測(按藥物、最終用戶、地區和競爭細分,2020-2030 年)

Oral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By End Users, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球口服抗糖尿病藥物市值為 180.2 億美元,預計到 2030 年將達到 259.4 億美元,預測期內複合年成長率為 6.22%。由於全球糖尿病盛行率的上升和藥物研究的不斷進步,該市場經歷了顯著的成長。受人口老化、久坐不動的生活方式和不健康飲食等因素的影響,糖尿病患者數量龐大且不斷成長。因此,對多樣化和有效的口腔治療方案的需求激增。市場涵蓋多種藥物類別,包括磺醯脲類藥物、雙胍類藥物、DPP-4 抑制劑、SGLT2 抑制劑和 GLP-1 受體激動劑,每種藥物都針對不同的血糖控制機制。競爭依然激烈,老牌製藥巨頭和新興公司都在努力創新,爭取更大的市場佔有率。對改進糖尿病管理解決方案的日益成長的需求繼續刺激著這個充滿活力和重要的醫療保健領域的研究和投資。

市場概覽
預測期 2026-2030
2024年市場規模 180.2億美元
2030年市場規模 259.4億美元
2025-2030 年複合年成長率 6.22%
成長最快的領域 醫院
最大的市場 北美洲

關鍵市場促進因素

全球糖尿病盛行率不斷上升

主要市場挑戰

高昂的醫療費用

主要市場趨勢

個人化醫療方法

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球口服抗糖尿病藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物(雙胍類、α-葡萄糖苷酶抑制劑、多巴胺-D2 受體激動劑、鈉-葡萄糖協同轉運蛋白-2(SGLT-2)抑制劑、二肽基肽酶-4(DPP-4)抑制劑、磺醯脲類、格列奈類)
    • 最終使用者(醫院、家庭護理、專科中心等)
    • 按公司分類(2024)
    • 按地區
  • 市場地圖

第6章:北美口服抗糖尿病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章:歐洲口服抗糖尿病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太口服抗糖尿病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章:南美洲口服抗糖尿病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東和非洲口服抗糖尿病藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章: 大環境分析

第 14 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代藥物的威脅

第 15 章:競爭格局

  • KONINKLIJKE PHILIPS NV
  • Sanofi SA
  • Eli Lilly and Company
  • AstraZeneca
  • Astellas Pharma Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Boehringer Ingelheim
  • Merck And Co.
  • Bristol Myers Squibb Company
  • Novartis AG

第 16 章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16137

The Global Oral Anti-Diabetic Drugs Market was valued at USD 18.02 Billion in 2024 and is projected to reach USD 25.94 Billion by 2030, growing at a CAGR of 6.22% during the forecast period. This market has witnessed notable growth due to the rising global prevalence of diabetes and continuous advancements in pharmaceutical research. Diabetes, driven by factors such as aging populations, sedentary lifestyles, and unhealthy diets, has created a vast and growing patient pool. As a result, the need for diverse and effective oral treatment options has surged. The market encompasses a wide array of drug classes, including Sulfonylureas, Biguanides, DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1 Receptor Agonists, each addressing different mechanisms of glucose control. Competition remains robust, with established pharmaceutical giants and emerging companies striving for innovation and greater market share. The growing demand for improved diabetes management solutions continues to stimulate research and investment across this dynamic and essential healthcare sector.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 18.02 Billion
Market Size 2030USD 25.94 Billion
CAGR 2025-20306.22%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Increasing Global Diabetes Prevalence

The rapidly growing incidence of diabetes globally is a key force driving the Oral Anti-Diabetic Drugs (OAD) market. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 are living with diabetes in 2024, representing 11.1% of the global adult population. This number is expected to rise to 643 million by 2030 and 853 million by 2050. A 2024 Lancet study further highlights that around 828 million adults were affected by diabetes as of 2022. This sharp increase is attributed to lifestyle changes including physical inactivity, poor nutrition, and population aging. These factors significantly elevate the risk of type 2 diabetes, prompting a surge in demand for effective oral therapies. As the diabetic population grows, so does the need for accessible and reliable medications, underscoring the crucial role of oral anti-diabetic drugs in modern disease management.

Key Market Challenges

High Healthcare Costs

One of the major challenges in the Oral Anti-Diabetic Drugs market is the high cost associated with comprehensive diabetes care. This includes not only medications but also glucose monitoring devices, routine consultations, and hospitalization in case of complications. For many patients-especially in low- and middle-income countries-the affordability and accessibility of these treatments remain significant concerns. The price of oral anti-diabetic drugs forms a substantial part of diabetes-related expenditures, and for those lacking adequate insurance or financial support, these expenses can be burdensome. This economic pressure can result in reduced adherence to treatment regimens, ultimately impacting health outcomes and exacerbating disease progression. Managing these cost-related challenges is essential to ensure broader access to effective diabetes therapies.

Key Market Trends

Personalized Medicine Approaches

Personalized medicine is emerging as a transformative trend in the Oral Anti-Diabetic Drugs market. Recognizing that diabetes is a complex and heterogeneous condition, healthcare providers are moving towards customized treatment strategies tailored to each patient's genetic makeup, comorbidities, and personal preferences. Advances in genetic testing and biomarker analysis now allow for more accurate drug selection and dosing, enhancing treatment efficacy while reducing the risk of adverse effects. The shift away from a "one-size-fits-all" model is improving patient outcomes and safety. Personalized therapies are particularly valuable in complex cases where standard treatments may not deliver optimal results, making this trend a key driver of innovation and patient satisfaction in the market.

Key Market Players

  • KONINKLIJKE PHILIPS N.V.
  • Sanofi S.A.
  • Eli Lilly and Company
  • AstraZeneca
  • Astellas Pharma Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Boehringer Ingelheim
  • Merck And Co.
  • Bristol Myers Squibb Company
  • Novartis AG

Report Scope:

In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Anti-Diabetic Drugs Market, By Drugs:

  • Biguanides
  • Alpha-glucosidase inhibitors
  • Dopamine -D2 Receptor Agonist
  • Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
  • Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
  • Sulfonylureas
  • Meglitinides

Oral Anti-Diabetic Drugs Market, By End Users:

  • Hospitals
  • Homecare
  • Speciality Centers
  • Others

Oral Anti-Diabetic Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market.

Available Customizations:

Global Oral Anti-Diabetic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Anti-Diabetic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides)
    • 5.2.2. End Users (Hospitals, Homecare, Speciality Centres, Others)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Oral Anti-Diabetic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By End Users
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By End Users
    • 6.3.2. Mexico Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By End Users
    • 6.3.3. Canada Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By End Users

7. Europe Oral Anti-Diabetic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By End Users
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By End Users
    • 7.3.2. Germany Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By End Users
    • 7.3.3. United Kingdom Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By End Users
    • 7.3.4. Italy Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By End Users
    • 7.3.5. Spain Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By End Users

8. Asia-Pacific Oral Anti-Diabetic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By End Users
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By End Users
    • 8.3.2. India Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By End Users
    • 8.3.3. South Korea Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By End Users
    • 8.3.4. Japan Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drugs
        • 8.3.4.2.2. By End Users
    • 8.3.5. Australia Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drugs
        • 8.3.5.2.2. By End Users

9. South America Oral Anti-Diabetic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By End Users
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By End Users
    • 9.3.2. Argentina Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By End Users
    • 9.3.3. Colombia Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By End Users

10. Middle East and Africa Oral Anti-Diabetic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By End Users
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By End Users
    • 10.3.2. Saudi Arabia Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By End Users
    • 10.3.3. UAE Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By End Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Drugs

15. Competitive Landscape

  • 15.1. KONINKLIJKE PHILIPS N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed companies)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Sanofi S.A.
  • 15.3. Eli Lilly and Company
  • 15.4. AstraZeneca
  • 15.5. Astellas Pharma Inc.
  • 15.6. Johnson & Johnson (Janssen Pharmaceuticals)
  • 15.7. Boehringer Ingelheim
  • 15.8. Merck And Co.
  • 15.9. Bristol Myers Squibb Company
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer